Results 191 to 200 of about 6,612,897 (317)

Characterizing epithelial‐mesenchymal transition‐linked heterogeneity in breast cancer circulating tumor cells at a single‐cell level

Molecular Oncology, EarlyView.
In over 50% of non‐metastatic breast cancer patients, circulating tumor cells (CTCs) along the whole epithelial‐mesenchymal transition spectrum are detected. Total CTC number and individual phenotypes relate to aggressive disease characteristics, including lymph node involvement and higher tumor proliferation. At the single‐cell level, mesenchymal CTCs
Justyna Topa, Julia Richert, Tomasz Stokowy, Alicja Staśczak, Mariusz Szajewski, Maciej Ciesielski, Petra M. Grešner, Bartłomiej Tomasik, Łukasz Arcimowicz, Agnieszka Stankiewicz, Grażyna Suchodolska, Elżbieta Senkus, Wiesław Kruszewski, Anna J. Żaczek, Aleksandra Markiewicz   +14 more
wiley   +1 more source

Potential drug-drug interactions among hospitalised cardiac patients in Nepal: a prospective observational study. [PDF]

BMJ Open
Sah BK, Karna AK, Subedi S, Sah RK, Shrestha S, Dangi NB.   +5 more
europepmc   +1 more source

DRUG INTERACTIONS IN ANAESTHESIA

, 1974
A. W. Grogono
openalex   +1 more source

The Interaction of d-Tubocurarine with Antiarrhythmic Drugs [PDF]

, 1970
Marvin D. Harrah, Walter L. Way, Bertram G. Katzung   +2 more
openalex   +1 more source

The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity

Molecular Oncology, EarlyView.
Natural killer (NK) cells play a central role in anti‐melanoma immunity. However, melanoma cells adapt during co‐culture by upregulating CIITA and MHC II in response to interferon gamma (IFNγ), thereby evading NK‐cell lysis. Blocking IFNγ signaling or treatment with dimethyl fumarate/simvastatin counteracts this immune escape and maintains NK‐cell ...
Lena C. M. Krause, Rixa‐Mareike Köhn, Christian Ickes, Julia Lenger, Jonas Fischer, Sabrina Cappello, Ivan Bogeski   +6 more
wiley   +1 more source

The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data

Pharmacogenomics and Personalized Medicine
Nina L Wittwer,1,2 Christoph R Meier,1– 3 Carola A Huber,4 Julie D Moser,1 Henriette E Meyer zu Schwabedissen,5 Samuel S Allemann,6,* Cornelia Schneider1,2,* 1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology,
Wittwer NL, Meier CR, Huber CA, Moser JD, Meyer zu Schwabedissen HE, Allemann SS, Schneider C   +6 more
doaj  

Prevalence and Clinical Significance of Potential Drug-Drug Interactions in Hospitalized Pediatric Oncology Patients: A Prospective Pharmacoepidemiologic Study. [PDF]

Cancers (Basel)
Zekavat OR, Zarsanj N, Sadeghdoust A, Lavu A, Bordbar M, Eltonsy S, Peymani P.   +6 more
europepmc   +1 more source

Interaction of Drugs, Steroids and Fatty Acids with Liver-Microsomal Cytochrome P-450 [PDF]

, 1970
David Kupfer, Sten Orrenius
openalex   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Editorial: Benefit and risk on drug-drug interactions in infections. [PDF]

Front Microbiol
Kato H, Asai N, Hagihara M.
europepmc   +1 more source